EARLY INITIATION OF ANTIPLATELET THERAPY IN HEART TRANSPLANTATION (AERIAL)

Registry ID

CTO 3464

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

OTTAWA HEART INSTITUTE RESEARCH CORPORATION

Start date

2025-12-12

Last update

2021-04-06

Conditions

• TRANSPLANTATION

Related clinical trials

• PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, WITH CROSS-OVER, OF POSOLEUCEL (ALVR105) FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC AND ADULT PARTICIPANTS RECEIVING STANDARD OF CARE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
• A RANDOMIZED TRIAL OF LOW VERSUS MODERATE EXPOSURE BUSULFAN FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY (SCID) RECEIVING TCR¿¿+/CD19+ DEPLETED TRANSPLANTATION: A PHASE II STUDY BY THE PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM (PIDTC) AND PEDIATRIC TRANSPLANTATION & CELLULAR THERAPY CONSORTIUM (PTCTC) PIDTC ¿CSIDE¿ PROTOCOL (CONDITIONING SCID INFANTS DIAGNOSED EARLY) PTCTC NMD1801
• CALCINEURIN INHIBITORS IN NEUROLOGICALLY DECEASED DONORS TO DECREASE KIDNEY DELAYED GRAFT FUNCTION (CINERGY)-PILOT
• A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CINRYZE (C1 ESTERASE INHIBITOR (HUMAN)) FOR THE TREATMENT OF ACUTE ANTIBODY-MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT PATIENTS
• ALLOGENEIC ISLET CELLS TRANSPLANTED INTO THE OMENTUM
• RANDOMIZED CONTROLLED TRIAL OF INFLIXIMAB INDUCTION THERAPY FOR DECEASED DONOR KIDNEY TRANSPLANT RECIPIENTS

View on source registry